Growth Strategy Overview

Sanofi has constantly followed the strategy of acquisitions and partnerships in order to grow
as a global health care provider. By this the company creates shareholder value by creating or
reinforcing platforms for long term growth.
The seven growth platform in which the company invested are as follows:
1. Emerging Markets: Sanofi is the #1 healthcare company in Emerging Markets with
a broad product portfolio adapted to local needs.
2. Diabetes Solutions: Lantus, basal insulin, is the worlds leading diabetes brand.
3. Human Vaccines: Sanofi Pasteur offers a broad range of vaccines against 20 serious
diseases and is the undisputed leader in flu vaccines.
4. Consumer Healthcare (CHC): Sanofi is the world's 3rd largest CHC player.
5. Genzyme: a leader in biotechnology, is our global center for excellence in rare
diseases and multiple sclerosis.
6. Animal Health: Merial is a global leader in Animal Health with expertise in both
veterinary pharmaceutical products and vaccines.
7. Other Innovative Products: On Feburary 6, 2014, the R&D portfolio included 49
projects, 12 of which were in Phase III or had been submitted for approval.
Diversification

Consumer healthcare : Building portfolio through target acquisition
Laboratoire Oenobiol in France.
Kernpharm in the Netherlands.
Chattem in the United State.
Nepentes S.A in Poland.
BMP Sunstone in China.
Candem Pharma in Canada.
Minsheng Pharmaceuticals Co. Ltd in China.

2. Animal health : Through acquisition of Merial, they have ventured into the
research, development, manufacture and commercialization of
innovative pharmaceutical products and vaccines for animals with principle markets
such as United States, France, Italy, the United Kingdom, Brazil, Australia, Japan,
Germany, Spain and Canada
Market Penetration

1. Elder Pharma (2013): To deepen its penetration into $13 billion Indian
Pharmaceutical market.
2. Universal Medicare (2011): Acquired branded nutraceutical formulations business of
Mumbai-based Universal Medicare Pvt Ltd to reinforce their commitment to invest
and grow their presence in India through a diversified portfolio that is focused on
patients' needs.
3. Nichi-iko pharmaceutical co. ltd: Signed an agreement with a rapidly growing
company that leads the Japanese generics market
Sanofi continues to strengthen its Generic activities. This is particularly visible in
Emerging Markets, with the acquisitions of:
Medley (2009): Acquired Brazilian generic drug manufacturer to extend their
Pharmaceutical portfolio in emerging market.
Zentiva (2009): Acquired Czech Generic drug maker to increase their
presence in Central end Eastern Europe.
Labratorios Kendrick (2009): Acquired Mexican generic drug maker to
build foothold in therapeutic areas.




Research and Development

1. Bipar Science: New selective anti-tumoral therapy for different types of cancers.
2. Fovea pharmaceutical: Specialized in opthamalogy
3. Covance(2010): Names Covance its R&D Partner to transform its R&D model and
discover new medicines through the use of novel technologies
4. Genzyme (2011): To gain competence in Biological drugs to have a strong presence
in research in the U.S.